Two Sigma Securities’s Cullinan Oncology CGEM Stock Holding History

Two Sigma Securities’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24,640	Closed	-$316K	–	2646
2022 Q2	$316K	Buy	+24,640	New	+$279K	0.01%	1254

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Two Sigma Securities's CGEM Position: Q3 2022 in Review

Two Sigma Securities sold out of Cullinan Oncology (CGEM) in Q3 2022, closing a stake of 24,640 shares — an estimated $316K sold.

Two Sigma Securities first reported a position in CGEM in Q2 2022 and held it in 1 quarter. The position peaked at $316K in Q2 2022. 99 funds tracked by Wall St. Rank hold CGEM as of Q3 2022.

Two Sigma Securities reported no remaining Cullinan Oncology position as of Q3 2022 after selling out during the quarter.
Two Sigma Securities sold 24,640 Cullinan Oncology shares in Q3 2022, an estimated $316K.
Two Sigma Securities first reported a position in Cullinan Oncology in Q2 2022 and held it in 1 quarter.
Two Sigma Securities's Cullinan Oncology position peaked at $316K in Q2 2022.
99 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2022.

Based on Two Sigma Securities's 13F filing for Q3 2022, filed 14 Nov 2022.